Leo Fu
Co-Founder & Chief Technology Officer GluBio
Seminars
Wednesday 28th October 2026
AI-Driven Rational Design of VAV1 Molecular Glue Degrader GLB-008: From Discovery to Preclinical Differentiation
2:45 pm
- AI-powered rational design and structural insights enabled discovery and optimization of VAV1 molecular glue degraders with enhanced potency, selectivity, and drug-like properties
- GLB-008 demonstrates a differentiated preclinical profile characterized by robust VAV1 degradation and disease-relevant functional activity in autoimmune assays
- Integrated PK/PD, efficacy, and safety data de-risk GLB-008 and support its informed progression toward clinical development
